MétaCan
Menu
Back to cohort
Record W4406034549 · doi:10.1080/03007995.2024.2440059

Effects of brexpiprazole on patient life engagement in schizophrenia: <i>post hoc</i> analysis of Positive and Negative Syndrome Scale data

2025· review· en· W4406034549 on OpenAlexaff
Zahinoor Ismail, Stine R. Meehan, Anja Farovik, Anton M. Palma, Zhen Zhang, Roger S. McIntyre

Bibliographic record

VenueCurrent Medical Research and Opinion · 2025
Typereview
Languageen
FieldMedicine
TopicSchizophrenia research and treatment
Canadian institutionsUniversity of TorontoUniversity of Calgary
FundersH. Lundbeck A/S
KeywordsMedicinePositive and Negative Syndrome ScalePost-hoc analysisSchizophrenia (object-oriented programming)Post hocPsychiatryNegative symptomScale (ratio)Clinical psychologyInternal medicinePsychosis

Abstract

fetched live from OpenAlex

Objective Patients with schizophrenia value improved life engagement, a term that describes positive health aspects across emotional, physical, social, and cognitive domains. This post hoc analysis of clinical trial data aimed to investigate the effect of brexpiprazole on patient life engagement in schizophrenia over the short and long term.Methods Data were pooled from three 6-week, randomized, double-blind, placebo-controlled clinical trials (ClinicalTrials.gov identifiers: NCT01396421, NCT01393613, NCT01810380; N = 1385) and two 52-week, open-label extension studies (NCT01397786, NCT01810783; N = 408) of brexpiprazole in adults with schizophrenia. Patient life engagement was measured using a subset of 14 Positive and Negative Syndrome Scale items (score range: 14 [best] to 98 [worst]) that has previously demonstrated content validity. Mean score changes and response rates (based on minimal clinically important difference estimates of ≥5 and ≥10 points) were calculated.Results Greater improvement in patient life engagement from baseline to Week 6 was observed for brexpiprazole 2–4 mg/day (least squares mean [standard error] change: −8.3 [0.3]; n = 868) versus placebo (−5.7 [0.4]; n = 517), with a least squares mean difference of −2.58 (95% confidence interval: −3.57 to −1.58; p < 0.001; Cohen’s d effect size: 0.28). These improvements were maintained over 58 weeks on brexpiprazole 1–4 mg/day (n = 399). At Week 6, response rates among patients treated with brexpiprazole versus placebo were 71.6% versus 58.0% (≥5-point improvement; p < 0.001) and 43.5% versus 32.8% (≥10-point improvement; p < 0.001). At Week 58 (n = 179), response rates among patients treated with brexpiprazole were 90.5% (≥5-point improvement) and 78.2% (≥10-point improvement).Conclusion Beyond its efficacy on psychotic symptoms, brexpiprazole has the potential to improve patient life engagement – an important patient-centered outcome in schizophrenia.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.013
metaresearch head score (Gemma)0.014
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.013
Threshold uncertainty score0.071

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0130.014
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.007
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.096
GPT teacher head0.454
Teacher spread0.358 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCurrent Medical Research and OpinionSame topicSchizophrenia research and treatmentFrench-language works237,207